Clinical Trial Update: A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL [Phase 1]

View source ↗

Summary

Phase 1 study evaluating glofitamab in combination with either rituximab or obinutuzumab plus CHOP, or polatuzumab vedotin plus rituximab with CHP, in participa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Glofitamab (glofitamab)
• Obinutuzumab (obinutuzumab)
• Rituximab (rituximab)
• polatuzumab vedotin (polatuzumab vedotin)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: B-Cell Lymphoma, Non-Hodgkin Lymphoma | Phase 1 | Status: COMPLETED